<?xml version='1.0' encoding='utf-8'?>
<document id="25316572"><sentence text="Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin."><entity charOffset="76-89" id="DDI-PubMed.25316572.s1.e0" text="ipragliflozin" /></sentence><sentence text="Ipragliflozin (Suglat(®)) is a potent and selective inhibitor of sodium-glucose cotransporter-2 that was recently launched in Japan"><entity charOffset="0-13" id="DDI-PubMed.25316572.s2.e0" text="Ipragliflozin" /><entity charOffset="65-79" id="DDI-PubMed.25316572.s2.e1" text="sodium-glucose" /><pair ddi="false" e1="DDI-PubMed.25316572.s2.e0" e2="DDI-PubMed.25316572.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25316572.s2.e0" e2="DDI-PubMed.25316572.s2.e1" /></sentence><sentence text=" Its mechanism of action involves the suppression of glucose re-absorption in the kidney proximal tubules, causing excretion of glucose in the urine"><entity charOffset="53-60" id="DDI-PubMed.25316572.s3.e0" text="glucose" /><entity charOffset="128-135" id="DDI-PubMed.25316572.s3.e1" text="glucose" /><pair ddi="false" e1="DDI-PubMed.25316572.s3.e0" e2="DDI-PubMed.25316572.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25316572.s3.e0" e2="DDI-PubMed.25316572.s3.e1" /></sentence><sentence text=" The aim of this review is to provide a comprehensive overview of currently available pharmacokinetic and pharmacodynamic data on ipragliflozin, including studies in healthy subjects, patients with type 2 diabetes mellitus and special populations"><entity charOffset="130-143" id="DDI-PubMed.25316572.s4.e0" text="ipragliflozin" /></sentence><sentence text=" In single- and multiple-dose studies, the maximum plasma concentration and area under the plasma concentration-time curve (AUC) for ipragliflozin increased in a dose-dependent manner"><entity charOffset="133-146" id="DDI-PubMed.25316572.s5.e0" text="ipragliflozin" /></sentence><sentence text=" Although urinary excretion of ipragliflozin is low (approximately 1 %), tubular concentration of free ipragliflozin is adequate to provide pharmacological activities"><entity charOffset="31-44" id="DDI-PubMed.25316572.s6.e0" text="ipragliflozin" /><entity charOffset="103-116" id="DDI-PubMed.25316572.s6.e1" text="ipragliflozin" /><pair ddi="false" e1="DDI-PubMed.25316572.s6.e0" e2="DDI-PubMed.25316572.s6.e0" /><pair ddi="false" e1="DDI-PubMed.25316572.s6.e0" e2="DDI-PubMed.25316572.s6.e1" /></sentence><sentence text=" No clinically relevant effects of age, gender or food on the exposure of ipragliflozin were observed"><entity charOffset="74-87" id="DDI-PubMed.25316572.s7.e0" text="ipragliflozin" /></sentence><sentence text=" The AUC for ipragliflozin was 20-30 % greater in patients with moderate renal or hepatic impairment than in patients with normal renal or hepatic function"><entity charOffset="13-26" id="DDI-PubMed.25316572.s8.e0" text="ipragliflozin" /></sentence><sentence text=" In drug-drug interaction studies, the pharmacokinetics of ipragliflozin and other oral antidiabetic drugs (metformin, sitagliptin, pioglitazone, glimepiride, miglitol and mitiglinide) were not significantly affected by their co-administration"><entity charOffset="59-72" id="DDI-PubMed.25316572.s9.e0" text="ipragliflozin" /><entity charOffset="108-117" id="DDI-PubMed.25316572.s9.e1" text="metformin" /><entity charOffset="119-130" id="DDI-PubMed.25316572.s9.e2" text="sitagliptin" /><entity charOffset="132-144" id="DDI-PubMed.25316572.s9.e3" text="pioglitazone" /><entity charOffset="146-157" id="DDI-PubMed.25316572.s9.e4" text="glimepiride" /><entity charOffset="159-167" id="DDI-PubMed.25316572.s9.e5" text="miglitol" /><entity charOffset="172-183" id="DDI-PubMed.25316572.s9.e6" text="mitiglinide" /><pair ddi="false" e1="DDI-PubMed.25316572.s9.e0" e2="DDI-PubMed.25316572.s9.e0" /><pair ddi="false" e1="DDI-PubMed.25316572.s9.e0" e2="DDI-PubMed.25316572.s9.e1" /><pair ddi="false" e1="DDI-PubMed.25316572.s9.e0" e2="DDI-PubMed.25316572.s9.e2" /><pair ddi="false" e1="DDI-PubMed.25316572.s9.e0" e2="DDI-PubMed.25316572.s9.e3" /><pair ddi="false" e1="DDI-PubMed.25316572.s9.e0" e2="DDI-PubMed.25316572.s9.e4" /><pair ddi="false" e1="DDI-PubMed.25316572.s9.e0" e2="DDI-PubMed.25316572.s9.e5" /><pair ddi="false" e1="DDI-PubMed.25316572.s9.e0" e2="DDI-PubMed.25316572.s9.e6" /><pair ddi="false" e1="DDI-PubMed.25316572.s9.e1" e2="DDI-PubMed.25316572.s9.e1" /><pair ddi="false" e1="DDI-PubMed.25316572.s9.e1" e2="DDI-PubMed.25316572.s9.e2" /><pair ddi="false" e1="DDI-PubMed.25316572.s9.e1" e2="DDI-PubMed.25316572.s9.e3" /><pair ddi="false" e1="DDI-PubMed.25316572.s9.e1" e2="DDI-PubMed.25316572.s9.e4" /><pair ddi="false" e1="DDI-PubMed.25316572.s9.e1" e2="DDI-PubMed.25316572.s9.e5" /><pair ddi="false" e1="DDI-PubMed.25316572.s9.e1" e2="DDI-PubMed.25316572.s9.e6" /><pair ddi="false" e1="DDI-PubMed.25316572.s9.e2" e2="DDI-PubMed.25316572.s9.e2" /><pair ddi="false" e1="DDI-PubMed.25316572.s9.e2" e2="DDI-PubMed.25316572.s9.e3" /><pair ddi="false" e1="DDI-PubMed.25316572.s9.e2" e2="DDI-PubMed.25316572.s9.e4" /><pair ddi="false" e1="DDI-PubMed.25316572.s9.e2" e2="DDI-PubMed.25316572.s9.e5" /><pair ddi="false" e1="DDI-PubMed.25316572.s9.e2" e2="DDI-PubMed.25316572.s9.e6" /><pair ddi="false" e1="DDI-PubMed.25316572.s9.e3" e2="DDI-PubMed.25316572.s9.e3" /><pair ddi="false" e1="DDI-PubMed.25316572.s9.e3" e2="DDI-PubMed.25316572.s9.e4" /><pair ddi="false" e1="DDI-PubMed.25316572.s9.e3" e2="DDI-PubMed.25316572.s9.e5" /><pair ddi="false" e1="DDI-PubMed.25316572.s9.e3" e2="DDI-PubMed.25316572.s9.e6" /><pair ddi="false" e1="DDI-PubMed.25316572.s9.e4" e2="DDI-PubMed.25316572.s9.e4" /><pair ddi="false" e1="DDI-PubMed.25316572.s9.e4" e2="DDI-PubMed.25316572.s9.e5" /><pair ddi="false" e1="DDI-PubMed.25316572.s9.e4" e2="DDI-PubMed.25316572.s9.e6" /><pair ddi="false" e1="DDI-PubMed.25316572.s9.e5" e2="DDI-PubMed.25316572.s9.e5" /><pair ddi="false" e1="DDI-PubMed.25316572.s9.e5" e2="DDI-PubMed.25316572.s9.e6" /></sentence><sentence text=" Urinary glucose excretion (UGE) also increased in a dose-dependent manner, approaching a maximum effect at 50-100 mg dosages in Japanese healthy volunteers and patients with type 2 diabetes"><entity charOffset="9-16" id="DDI-PubMed.25316572.s10.e0" text="glucose" /></sentence><sentence text=" The change in UGE from baseline (ΔUGE) tended to be lower in older subjects and female subjects, compared with younger subjects and male subjects, respectively" /><sentence text=" ΔUGE tended to decrease with decreasing renal function, especially in patients with type 2 diabetes with moderate or severe renal impairment" /><sentence text=" " /></document>